Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.

Jacob E OllechSujaata DwadasiVictoria RaiNoam PelegInessa NormatovAmanda IsraelPhilip H SossenheimerBritt ChristensenJoel PekowSushila R DalalAtsushi SakurabaRussell D CohenDavid T Rubin

Published in: Alimentary pharmacology & therapeutics (2019)

Transitioning to vedolizumab following induction of remission with CNIs is effective and safe.

Keyphrases

ulcerative colitis
early onset
stem cells
rheumatoid arthritis
systemic lupus erythematosus
bone marrow